The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer’s disease
Open accessAbstract
See Grinberg and Heinsen (doi:10.1093/brain/awx261) for a scientific commentary on this article. Clinical evidence suggests that aberrant tau accumulation in the locus coeruleus and noradrenergic dysfunction may be a critical early step in Alzheimer’s disease progression. Yet, an accurate preclinical model of these phenotypes that includes early pretangle tau accrual in the locus coeruleus, loss of locus coeruleus innervation and deficits locus coeruleus/norepinephrine modulated behaviours, does not exist, hampering the identification of underlying mechanisms and the development of locus coeruleus-based therapies. Here, a transgenic rat (TgF344-AD) expressing disease-causing mutant amyloid precursor protein (APPsw) and presenilin-1 (PS1ΔE9) was characterized for histological and behavioural signs of locus coeruleus dysfunction reminiscent of mild cognitive impairment/early Alzheimer’s disease. In TgF344-AD rats, hyperphosphorylated tau was detected in the locus coeruleus prior to accrual in the medial entorhinal cortex or hippocampus, and tau pathology in the locus coeruleus was negatively correlated with noradrenergic innervation in the medial entorhinal cortex. Likewise, TgF344-AD rats displayed progressive loss of hippocampal norepinephrine levels and locus coeruleus fibres in the medial entorhinal cortex and dentate gyrus, with no frank noradrenergic cell body loss. Cultured mouse locus coeruleus neurons expressing hyperphosphorylation-prone mutant human tau had shorter neurites than control neurons, but similar cell viability, suggesting a causal link between pretangle tau accrual and altered locus coeruleus fibre morphology. TgF344-AD rats had impaired reversal learning in the Morris water maze compared to their wild-type littermates, which was rescued by chemogenetic locus coeruleus activation via designer receptors exclusively activated by designer drugs (DREADDs). Our results indicate that TgF344-AD rats uniquely meet several key criteria for a suitable model of locus coeruleus pathology and dysfunction early in Alzheimer’s disease progression, and suggest that a substantial window of opportunity for locus coeruleus/ norepinephrine-based therapeutics exists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The brain noradrenergic system is also critical for cognition and noradrengergic dysfunction is a critical early step in AD progression 249.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [249]
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
The locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848
The efficiency of systematic sampling in stereology—reconsidered
GUNDERSEN, H. J. G., JENSEN, E. B. V., KIÊU, K., & NIELSEN, J. (1999) · Journal of Microscopy · doi:10.1046/j.1365-2818.1999.00457.x · Cited by 1,317
Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998
The dentate gyrus: fundamental neuroanatomical organization (dentate gyrus for dummies)
Amaral, D. G., Scharfman, H. E., & Lavenex, P. (2007) · Progress in brain research · doi:10.1016/s0079-6123(07)63001-5 · Cited by 888
Al-Atrache, Z., Cader, A., & Appelt, D. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.894 · Cited by 765
Cited by
Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., et al. (2019) · Brain · doi:10.1093/brain/awz193 · Cited by 365
“In animal models, lesions of the LC have been shown to exacerbate tau and amyloid-b plaque deposition, leading to depletion of noradrenaline in LC target regions and impaired cognitive function (Heneka, 2006; Kalinin et al., 2006, 2012; Jardanhazi-Kurutz et al., 2010; Chalermpalanupap et al., 2017; Rorabaugh et al., 2…”
BackgroundLong Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease
Weinshenker, D. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.01.010 · Cited by 323
“, chemogenetic/optogenetic facilitation, NE prodrugs/agonists/reuptake inhibitors, aerobic exercise, environmental enrichment) could be of benefit, as already shown for animal models and in some human studies [16,17,21,30,42,130,131].”
InfluentialSelf-citationYan, Z., & Rein, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01092-3 · Cited by 300
“The brain noradrenergic system is also critical for cognition and noradrenergic dysfunction is a critical early step in AD progression [249].”
BackgroundXiao, W., Su, J., Gao, X., Yang, H., Weng, R., Ni, W., & Gu, Y. (2022) · Microbiome · doi:10.1186/s40168-022-01255-6 · Cited by 252
“Hippocampal changes underlie the cognitive decline in chronological aging and CNS diseases like AD [54, 55].”
BackgroundJacobs, H. I. L., Becker, J. A., Kwong, K. K., Engels, N., Prokopiou, P. C., Papp, K. V., Properzi, M. J., Hampton, O. L., Uquillas, F. D., Sanchez, J. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj2511 · Cited by 239
Metadata
- Authors
- Rorabaugh, J. M., Chalermpalanupap, T., Botz-Zapp, C. A., Fu, V. M., Lembeck, N. A., Cohen, R. M., & Weinshenker, D.
- Affiliations
- Emory University (US)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-09-25
- Volume
- 140
- Issue
- 11
- Pages
- 3023-3038
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC5841201
- OpenAlex
- W2760256027
- Cited by
- 227
- References
- 72
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 39 · 2023: 20 · 2022: 45 · 2021: 26 · 2020: 18 · 2019: 14 · 2018: 13 · 2017: 3
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (AG0476670, NS007480)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- locus coeruleus, Alzheimer's disease, reversal learning, tau hyperphosphorylation, noradrenergic dysfunction, norepinephrine, TgF344-AD rats, medial entorhinal cortex, DREADD, chemogenetic activation, mild cognitive impairment, preclinical models
- MeSH terms
- Alzheimer Disease, Animals, Cells, Cultured, Disease Models, Animal, Female, Locus Coeruleus, Male, Rats, Inbred F344, Reversal Learning, tau Proteins, Maze Learning, Rats, Rats, Transgenic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer’s disease. https://app.cochat.ai/papers/10.1093/brain/awx232
- The paper
- Rorabaugh, J. M., Chalermpalanupap, T., Botz-Zapp, C. A., Fu, V. M., Lembeck, N. A., Cohen, R. M., & Weinshenker, D. (2017). Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer’s disease. Brain. https://doi.org/10.1093/brain/awx232
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.